

APPENDIX: Primary Care Providers Questionnaire

11. Approximate percentage of these psychiatric patients that are being prescribed antipsychotic medications at risk for causing metabolic dysfunction, such as increased BMI, obesity, and diabetes (e.g. olanzapine, risperdone, chlorpromazine): _____ %

12. Are you aware of the ADA/APA (American Diabetes Association, American Psychiatric Association) consensus statement describing metabolic risks associated with second generation antipsychotic medications and specifying a monitoring protocol for patients taking these medications?

YES

NO

Physician Attitudes:

For each question, please circle the choice that best fits your response:

13. How strongly do you agree or disagree with the following statements?

a. **Individuals with schizophrenia are more at risk than the general population for suffering metabolic dysfunction, such as increased BMI, obesity, and diabetes.**

Strongly disagree

Disagree

Neutral

Agree

Strongly agree

b. **Some antipsychotic medications can contribute to metabolic dysfunction, such as increased BMI, obesity, and diabetes.**

Strongly disagree

Disagree

Neutral

Agree

Strongly agree

Physician Roles:

For each question, please circle the choice that best fits your response:

Roles in Monitoring:

14. How strongly do you agree or disagree with the following statements?

Monitoring metabolic risk factors (such as BMI, BP, glucose, and/or lipids) in patients on antipsychotics at risk of causing metabolic dysfunction is the role of:

a. **Primary care providers, not psychiatrists** or mental health clinics.

Strongly disagree

Disagree

Neutral

Agree

Strongly agree

b. The **psychiatrist or mental health clinic**, *only if* patients do not have an established primary care provider.

Strongly disagree

Disagree

Neutral

Agree

Strongly agree

c. The **psychiatrist or mental health clinic**, *even if* patients have established primary care.

Strongly disagree

Disagree

Neutral

Agree

Strongly agree

→ Continue

Roles in Treatment:

15. How strongly do you agree or disagree with the following statements about the responsibility of **community psychiatrists**?

If patients **in a mental health clinic** are found to have abnormalities in metabolic risk factors that are likely caused by treatment with antipsychotic medications, the following interventions may be the **responsibility of the treating psychiatrist**:

- a. Responsibility of **psychiatrists to refer to primary care providers** or other medical follow-up

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
-------------------	----------	---------	-------	----------------
- b. Responsibility of **psychiatrists to directly contact patients' primary care** or other medical providers

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
-------------------	----------	---------	-------	----------------
- c. Responsibility of **psychiatrists to maintain contact with primary care** or other medical providers regarding continuing treatment of metabolic risk factors

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
-------------------	----------	---------	-------	----------------
- d. Responsibility of **psychiatrists to provide patients with literature** regarding metabolic syndrome and related metabolic risk indicators

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
-------------------	----------	---------	-------	----------------
- e. Responsibility of **psychiatrists to refer patients to weight loss programs**, or other related psychosocial or support group programs

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
-------------------	----------	---------	-------	----------------
- f. Responsibility of **psychiatrists to refer patients to smoking cessation programs**

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
-------------------	----------	---------	-------	----------------

16. How strongly do you agree or disagree with the following statement?

- a. Prescribing oral medications to treat elements of metabolic dysfunction (e.g., statins, metformin) may, **in certain circumstances**, be the responsibility of **the outpatient treating psychiatrist**.

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
-------------------	----------	---------	-------	----------------

- b. In which of the following circumstances do you think it would be appropriate to have the **treating outpatient psychiatrist** prescribe oral medications to treat elements of metabolic dysfunction? Please select all that apply.

- In extremely rare circumstances (e.g., patients requesting emergency refills)
- Sharing responsibility for treatment in partnership with a primary care or other medical provider
- If a patient does not have access to primary care or other medical providers
- If the **psychiatrist** is the sole provider treating elements of metabolic dysfunction

→ Continue

Barriers to Monitoring:

17. In the following section, please rate the degree to which the factors listed below are significant barriers to monitoring *your* patients for metabolic risk. For each factor, circle one of the following that best suits your response to whether you agree or disagree that the factor is a significant barrier to monitoring: strongly disagree (1), disagree (2), neutral (3), agree (4), or strongly agree (5), or select N/A if the factor is not relevant to your patients or practice environment.

I believe the following **patient factors** are a barrier to monitoring patients for monitoring metabolic risk:

	Strongly disagree	Disagree	Neutral	Agree	Strongly agree	
Gender	1	2	3	4	5	N/A
Lack of insurance	1	2	3	4	5	N/A
Lack of income	1	2	3	4	5	N/A
Ethnic or cultural factors	1	2	3	4	5	N/A
Fluency of English	1	2	3	4	5	N/A
Legal status	1	2	3	4	5	N/A
Lack of education	1	2	3	4	5	N/A
Severity of psychiatric illness	1	2	3	4	5	N/A

I believe the following **staffing or physician factors (at your primary care clinic)** are a barrier to monitoring patients for monitoring metabolic risk:

	Strongly disagree	Disagree	Neutral	Agree	Strongly agree	
Insufficient staff availability	1	2	3	4	5	N/A
Insufficient staff awareness	1	2	3	4	5	N/A
Insufficient staff training	1	2	3	4	5	N/A
Insufficient physician time	1	2	3	4	5	N/A
Ability to counsel this population about metabolic problems	1	2	3	4	5	N/A
Ability to treat metabolic problems in this population	1	2	3	4	5	N/A
Insufficient reimbursement for screening	1	2	3	4	5	N/A
Insufficient reimbursement for treatment	1	2	3	4	5	N/A
Burden of documentation	1	2	3	4	5	N/A
Difficulty accessing laboratory data	1	2	3	4	5	N/A
Medicolegal liability of testing patients	1	2	3	4	5	N/A
Medicolegal liability of treatment	1	2	3	4	5	N/A

I believe the following **referral and collaboration factors** are a barrier to monitoring patients for monitoring metabolic risk in our health care system in San Francisco County:

	Strongly disagree	Disagree	Neutral	Agree	Strongly agree	
Difficulty arranging referral for psychiatric follow-up	1	2	3	4	5	N/A
Lack of access to psychiatric follow-up	1	2	3	4	5	N/A
Wait times for appointments for psychiatric follow-up	1	2	3	4	5	N/A
Difficulty collaborating with physicians providing psychiatric follow-up	1	2	3	4	5	N/A
Increased cost of collaborative care	1	2	3	4	5	N/A

→ Continue

18. Please use the below list of barriers to answer the following questions:

a. Please rank numerically (**with 1, 2, and 3**) what you think are the **top 3 barriers** in your practice to screening and monitoring patients on antipsychotics at risk for causing metabolic dysfunction:

- | | |
|--|---|
| <input type="checkbox"/> Gender | <input type="checkbox"/> Ability to counsel these patients about metabolic problems |
| <input type="checkbox"/> Lack of insurance | <input type="checkbox"/> Ability to treat metabolic problems in this population |
| <input type="checkbox"/> Lack of income | <input type="checkbox"/> Insufficient reimbursement for screening |
| <input type="checkbox"/> Ethnic or cultural factors | <input type="checkbox"/> Insufficient reimbursement for treatment |
| <input type="checkbox"/> Fluency of English | <input type="checkbox"/> Burden of documentation |
| <input type="checkbox"/> Legal status | <input type="checkbox"/> Difficulty accessing laboratory data |
| <input type="checkbox"/> Lack of education | <input type="checkbox"/> Medicolegal liability of testing patients |
| <input type="checkbox"/> Severity of psychiatric illness | <input type="checkbox"/> Medicolegal liability of treatment |
| <input type="checkbox"/> Insufficient staff availability | <input type="checkbox"/> Difficulty arranging referral for psychiatric follow-up |
| <input type="checkbox"/> Insufficient staff awareness | <input type="checkbox"/> Lack of access to qualified psychiatric follow-up |
| <input type="checkbox"/> Insufficient staff training | <input type="checkbox"/> Wait times for appointments for psychiatric follow-up |
| <input type="checkbox"/> Insufficient physician time | <input type="checkbox"/> Difficulty collaborating with psychiatrists |
| | <input type="checkbox"/> Increased cost of collaborative care |

b. If you could only choose **ONE** barrier from the above list of barriers that has the largest impact on screening, which would that be?

19. How strongly do you agree or disagree with the following statement?

Solving the **ONE** barrier I have listed above is likely to make a measurable impact in the rate of metabolic screening for patients at risk for developing metabolic dysfunction.

Strongly disagree Disagree Neutral Agree Strongly agree

Thank You!